- POSITIVE
Annual Revenue Avience Biomedicals Mar-2026 Annual Revenue is Rs 35 Cr which is growth of 20.2% YoY.
- POSITIVE
Annual Net Profit Avience Biomedicals Mar-2026 Annual Net Profit is Rs 7 Cr which is growth of 31.1% YoY.

Avience Biomedicals was incorporated on December 23, 2019. The company is engaged in the manufacturing of in-vitro diagnostic (IVD) products and medical devices from its facility in Noida, Uttar Pradesh. Its products support the detection of diseases, infections, and medical conditions through laboratory, healthcare, and home-based diagnostic testing applications
| Bidding Dates |
|---|
| 18 Jun 2026 - 22 Jun 2026 |
| Subscription |
|---|
| 355.06x Oversubscribed |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| ₹235,200 | 2 | 2 | 600 | 1.5 M | ₹196 - ₹208 | 64.59 % | ₹284.9 M - ₹302.4 M | RHP DOC |
Avience Biomedicals IPO SUBSCRIPTION STATUS
22 Jun '26Avience Biomedicals IPO overall subscription rate was 355.06 times the total available shares
Avience Biomedicals IPO retail subscription rate was 528.55 times in the retail segment
Avience Biomedicals IPO non-institutional investor subscription rate was 789.97 times in the non-institutional investor category
Avience Biomedicals IPO Qualified Institutional Bidder subscription rate was 103.14 times the available shares for Qualified Institutional Bidder
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
22 Jun 2026 (Day 3) | 528.55x | 789.97x | 103.14x |
19 Jun 2026 (Day 2) | 76.41x | 88.08x | 0.01x |
18 Jun 2026 (Day 1) | 20.06x | 17.75x | - |
Avience Biomedicals FINANCIALS
| Period | Revenue from Operations (Rs in crore) | Net Profit (Rs in crore) | Cash Flow from Operations (Rs in crore) | Free Cash Flow (Rs in crore) | Margins |
| 10MFY26 | 41.8 | 5.7 | 2.8 | -6.4 | 24.7% |
| FY25 | 45.2 | 7.2 | 3.6 | -4.7 | 25.2% |
| FY24 | 24.0 | 2.1 | 1.0 | -2.9 | 17.0% |
Avience Biomedicals IPO SUBSCRIPTION STATUS DETAILS
Avience Biomedicals had 1.5 M shares on offer
Avience Biomedicals IPO offer price was in the range ₹196 - ₹208
Avience Biomedicals IPO minimum Investment was ₹235200
Avience Biomedicals IPO issue size was ₹ 284.9 M - ₹ 302.4 M
Avience Biomedicals had a minimum lot size of 600 Shares per application
Avience Biomedicals NUMBER OF SHARES ON OFFER
Avience Biomedicals IPO IMPORTANT DATES
| Issue Open Date | 18 Jun 2026 |
| Issue close Date | 22 Jun 2026 |
| Allotment Date | 23 Jun 2026 |
| Refund Date | 24 Jun 2026 |
| Demat Account Credit Date | 24 Jun 2026 |
| Listing Date | 25 Jun 2026 |
| Listing on Exchange(s) | NSE |
| Avience Biomedicals Allotment Status | Exchange/ Registrar |
Avience Biomedicals IPO subscription opened on 18 Jun 2026, and closed on 22 Jun 2026
IPO allotment for Avience Biomedicals was finalized on Tuesday, 23 Jun 2026
IPO listing for Avience Biomedicals was on NSE on Thursday, 25 Jun 2026
Avience Biomedicals IPO LISTING GAINS
| Issue Price (adjusted) | 208.0 |
| Listing Open Price | 395.2 |
| Listing Close Price | 414.9 |
| Listing Gain% | 90.0% |
| Current Gain% | 26.9% |
Avience Biomedicals Peer
| Stock | Stock Price | Market Cap (Rs crore) | PE TTM | PEG TTM | PS TTM | ROE% | ROA% | Annual Revenue (Rs crore) | Annual Revenue Growth % | Annual Net Profit (Rs crore) | Annual Net Profit Growth % | EPS TTM | EPS TTM Growth % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avience Biomedicals Ltd. | 263.8 | 144.7 | 16.5 | 0.8 | 2.7 | 27.9 | 11.2 | 52.8 | 14.9 | 8.8 | 21 | 16 | 21 |
| Tarsons Products Ltd. | 303.4 | 1614.3 | 217.3 | -3.4 | 3.5 | 2.2 | 1.2 | 446.7 | 9.4 | 14.3 | -51.9 | 1.4 | -63.9 |
| Hemant Surgical Industries Ltd. | 590.3 | 769.7 | 42.3 | 13.2 | 6.6 | 237.7 | 112.7 | 18.2 | 126.2 | 14 | |||
| Fabtech Cleanrooms Ltd. | 414.3 | 510.4 | 32.3 | 15.2 | 8.5 | 221.7 | 46.9 | 15.8 | 19 | 12.8 | |||
| Prevest Denpro Ltd. | 369.3 | 443.3 | 21.6 | 1.4 | 5.7 | 16.4 | 15.4 | 76.7 | 14.4 | 20.5 | 12.9 | 17.1 | 15.1 |
| QMS Medical Allied Services Ltd. | 170 | 328.8 | 27.6 | -0.4 | 1.7 | 11.4 | 5.6 | 173.9 | 10.3 | 11.9 | -1.5 | 6.2 | -73.9 |
Avience Biomedicals annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 |
|---|---|---|---|---|---|---|---|---|---|
48.2% | 96.9% | 35.5 | 29.5 | 16.6 | 10.9 | 10.2 | 1.2 | ||
Operating Exp. Ann. | 36.9% | 85.9% | 24.4 | 21.2 | 13.1 | 9.5 | 8.9 | 1.1 | |
Operating Profit Ann. | 98.2% | 155.6% | 10.9 | 7.7 | 3.2 | 1.4 | 1.2 | 0.1 | |
OPM Ann. % | 33.1% | 41.6% | 30.71% | 25.91% | 18.93% | 13.03% | 12.00% | 5.40% | |
37.5% | 88.2% | 26 | 22.6 | 14 | 10 | 9.2 | 1.1 | ||
EBITDA Ann. | 99.4% | 156.5% | 11.1 | 8.3 | 3.5 | 1.4 | 1.2 | 0.1 | |
EBITDA Ann. margin % | 33.4% | 35.8% | 31.23% | 28.10% | 21.22% | 13.15% | 12.02% | 6.76% | |
Interest Ann. | 26% | - | 0.6 | 0.7 | 0.4 | 0.3 | 0.2 | 0 | |
Depr. | 71% | - | 1 | 0.7 | 0.4 | 0.2 | 0.1 | 0 | |
PBT Ann. | 111.8% | 148.6% | 9.5 | 6.9 | 2.7 | 1 | 1 | 0.1 | |
Tax Ann. | 110.5% | - | 2.8 | 1.8 | 0.7 | 0.3 | 0.3 | 0 | |
112.3% | 131.9% | 6.7 | 5.1 | 2 | 0.7 | 0.7 | 0.1 | ||
Net Profit Ann. | 112.3% | 131.9% | 6.7 | 5.1 | 2 | 0.7 | 0.7 | 0.1 | |
NPM Ann. % | 43.3% | 35.3% | 19.06% | 17.77% | 12.20% | 6.48% | 7.02% | 4.20% | |
EPS Adj. latest Ann. | 111.5% | 161.8% | 12.3 | 9.4 | 3.6 | 1.3 | 1.3 | 0.1 |
Avience Biomedicals INFORMATION ON IPO ISSUE
About Avience Biomedicals
Avience Biomedicals was incorporated on December 23, 2019. The company is engaged in the manufacturing of in-vitro diagnostic (IVD) products and medical devices from its facility in Noida, Uttar Pradesh. Its products support the detection of diseases, infections, and medical conditions through laboratory, healthcare, and home-based diagnostic testing applications
Object of the Issue
- Part finances the capital expenditure towards setting up of a new manufacturing unit Gautam Buddha Nagar, Uttar Pradesh
- Funding the working capital requirement of the company
- To meet out the general corporate purposes
Avience Biomedicals - PROMOTERS
| Name |
|---|
| Dharam Deo Choudhary |
| Ram Nagina Choudhary |
| Deepa Choudhary |
| Janardan Pal |
Avience Biomedicals - MANAGEMENT & LEADERSHIP
| Name | Designation |
|---|---|
| Dharam Deo Choudhary | Chairman & Managing Director |
| Ram Nagina Choudhary | Whole Time Director |
| Deepa Choudhary | Director |
| Janardan Pal | Director |
| Om Prakash Pal | Independent Director |
| Pankaj Sharma | Independent Director |
Avience Biomedicals Book Running Lead Manager
Fintellectual Corporate Advisors Private Limited
ipo@fintellectualadvisors.com
Avience Biomedicals Registrar to the Offer
Skyline Financial Services Private Limited
ipo@skylinerta.com
Avience Biomedicals Strengths
Innovative product portfolio
The company offers a comprehensive portfolio of IVD rapid diagnostic tests and medical devices, including solutions for infectious disease detection, haematology, and biochemistry analysis. It also strengthens its product range through its association as a channel partner for Mindray, providing advanced diagnostic and laboratory equipment to healthcare providers
End to end support
The company has a dedicated team of service engineers that provides end-to-end support, including equipment installation, user training, and maintenance services. This enables healthcare facilities and laboratories to operate efficiently with minimal downtime and improved diagnostic productivity
Talented workforce & efficient operations
The company is supported by a skilled workforce across manufacturing, quality assurance, regulatory affairs, and technical support, with a strong focus on continuous training and innovation. Its efficient manufacturing processes and adherence to quality standards enable timely product delivery while maintaining flexibility to meet evolving healthcare market requirement
Avience Biomedicals Risks
Inventory management risk
The company’s medical devices and consumables have a limited shelf life, making timely production, storage, and distribution critical to its operations. Any disruption in warehousing, logistics, or supply chain activities could lead to inventory losses, delayed deliveries, and an adverse impact on business performance and financial condition
Competition & customer retention risk
The company’s revenue depends on the continued success of its existing product portfolio and customer relationships, as well as the market acceptance of new products and innovations. Any decline in product competitiveness, loss of key customers, or failure to adapt to changing market demands could adversely affect its revenue, market position, and financial performance
Depend on third-party logistics
The company relies on third-party logistics and transportation services for the timely movement of raw materials and finished products. Any disruption caused by transportation delays, accidents, natural disasters, or external factors could increase costs, affect supply chain efficiency, and adversely impact operations and customer deliveries
IPO FAQs
The promoters of the company are Dharam Deo Choudhary, Ram Nagina Choudhary, Deepa Choudhary and Janardan Pal.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.
The price band of the IPO is Rs 196.0 - 208.0.
The IPO application opens on Jun 18, 2026 and closes on Jun 22, 2026.
The minimum lot size for the IPO is 1200. The maximum lot size for the IPO is 1200.
For all category investors, the minimum application amount for this IPO is Rs. 235,200.0, the maximum value for this IPO is Rs 249,600.0.
This IPO will be allotted on Jun 23, 2026.
The refund will be credited to your account on Jun 24, 2026.
The allotted shares will be credited to your demat on Jun 24, 2026.
Avience Biomedicals Ltd.’s shares listed on the stock exchanges on Jun 25, 2026.
